HomeCompareNOXOF vs CL

NOXOF vs CL: Dividend Comparison 2026

NOXOF yields 4444.44% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NOXOF wins by $19857738408180.44M in total portfolio value
10 years
NOXOF
NOXOF
● Live price
4444.44%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19857738408180.48M
Annual income
$19,016,069,933,146,186,000.00
Full NOXOF calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — NOXOF vs CL

📍 NOXOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNOXOFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NOXOF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NOXOF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NOXOF
Annual income on $10K today (after 15% tax)
$377,777.78/yr
After 10yr DRIP, annual income (after tax)
$16,163,659,443,174,257,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, NOXOF beats the other by $16,163,659,443,174,253,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NOXOF + CL for your $10,000?

NOXOF: 50%CL: 50%
100% CL50/50100% NOXOF
Portfolio after 10yr
$9928869204090.26M
Annual income
$9,508,034,966,573,095,000.00/yr
Blended yield
95.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

NOXOF
No analyst data
Altman Z
-7.9
Piotroski
3/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NOXOF buys
0
CL buys
0
No recent congressional trades found for NOXOF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNOXOFCL
Forward yield4444.44%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$19857738408180.48M$41.0K
Annual income after 10y$19,016,069,933,146,186,000.00$5,451.69
Total dividends collected$19800558376185.16M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NOXOF vs CL ($10,000, DRIP)

YearNOXOF PortfolioNOXOF Income/yrCL PortfolioCL Income/yrGap
1← crossover$455,144$444,444.44$11,014$313.84+$444.1KNOXOF
2$19,392,277$18,905,272.87$12,200$415.44+$19.38MNOXOF
3$773,548,232$752,798,494.96$13,607$553.09+$773.53MNOXOF
4$28,891,953,466$28,064,256,857.57$15,301$741.41+$28891.94MNOXOF
5$1,010,538,077,568$979,623,687,360.21$17,374$1,002.00+$1010538.06MNOXOF
6$33,103,483,882,921$32,022,208,139,922.89$19,958$1,367.44+$33103483.86MNOXOF
7$1,015,787,352,937,823$980,366,625,183,097.90$23,243$1,887.87+$1015787352.91MNOXOF
8$29,201,617,438,828,424$28,114,724,971,184,950.00$27,512$2,642.43+$29201617438.80MNOXOF
9$786,606,051,433,916,900$755,360,320,774,370,600.00$33,197$3,759.22+$786606051433.88MNOXOF
10$19,857,738,408,180,478,000$19,016,069,933,146,186,000.00$40,973$5,451.69+$19857738408180.44MNOXOF

NOXOF vs CL: Complete Analysis 2026

NOXOFStock

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.

Full NOXOF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this NOXOF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NOXOF vs SCHDNOXOF vs JEPINOXOF vs ONOXOF vs KONOXOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.